Advanced Medical Solutions Group PLC (AMS), the UK-based specialist medical device company, has disclosed that Société Générale crossed the 5% voting rights threshold in the business on 5 November 2026. The French banking group now holds 11,291,327 shares, representing 5.108209% of voting rights, all held directly with no financial instruments involved. The notification, submitted to AMS on 6 November 2026, was made under DTR5 disclosure rules, which require major shareholders to report when their holdings cross defined regulatory thresholds. Investors may be watching this development as a sign of significant institutional interest in the wound-care and biosurgery group.

Key Points

  • Advanced Medical Solutions Group PLC (AMS), ISIN GB0004536594, listed on the London market
  • Société Générale has crossed the 5% voting rights threshold, holding 5.108209% of AMS shares directly
  • The threshold was crossed on 5 November 2026, with the issuer notified on 6 November 2026; total shares held stand at 11,291,327
  • Investors should watch for any further changes in Société Générale's position and any subsequent major shareholder disclosures from AMS

Société Générale Acquires Direct Stake of 5.108209% in AMS Voting Rights

The TR-1 standard notification form confirms that Société Générale, registered in London, United Kingdom, acquired voting rights in Advanced Medical Solutions Group PLC that caused its total holding to reach 5.108209% on 5 November 2026. All 11,291,327 voting rights are held directly under DTR5.1, with zero voting rights held through financial instruments. The announcement states that no previous notification position was disclosed, meaning this appears to represent the first time Société Générale has formally reported a notifiable stake in AMS at or above the 5% regulatory threshold.

Advanced Medical Solutions Group: UK Specialist in Wound Care and Biosurgery Products

Advanced Medical Solutions Group PLC is a UK-based medical device company focused on the development, manufacture, and distribution of wound-care management and biosurgery products. The company operates across international markets and supplies healthcare professionals and hospital networks with advanced tissue-healing technologies. AMS generates revenue through the commercialisation of branded and own-label products spanning wound closure, haemostats, and sealants. The company did not disclose any operational or financial updates in connection with this announcement, which is solely a regulatory major-holdings notification as required under UK Disclosure and Transparency Rules.

DTR5 Regulatory Obligation Drives the Major Holdings Disclosure

Under the Financial Conduct Authority's Disclosure and Transparency Rules, any person whose voting rights in a UK-listed issuer cross, reach, or fall below defined thresholds — including 5% — must notify the issuer promptly. Société Générale confirmed in the notification that it is not controlled by any natural person or legal entity and does not control any other undertaking holding an interest in AMS. The form was completed on 6 November 2026 in London. No proxy voting arrangements were disclosed. The announcement reflects standard regulatory compliance rather than any agreed commercial transaction between the two parties.